Literature DB >> 16633039

Use of nerve growth factor to treat congenital neurotrophic corneal ulceration.

Mei Hong Tan1, John Bryars, Jonathan Moore.   

Abstract

PURPOSE: This study was designed to assess the efficacy of nerve growth factor in the treatment of neurotrophic corneal ulceration in a child with bilateral congenital corneal anesthesia secondary to trigeminal insufficiency.
METHODS: A 5-month-old child presented to the casualty department with a 2-week history of red eyes and right corneal ulceration. Slit-lamp examination showed a central defect in the right corneal epithelium with underlying stromal opacification, only mild conjunctival inflammation with slight decreased tear production, and otherwise apparently normal eyes. Initially this was investigated as an infected ulcer and treated for several weeks as herpetic ulceration with no beneficial effect. Further clinical examination demonstrated bilateral decreased corneal sensation along with decreased facial sensation in keeping with congenital trigeminal nerve insufficiency. Investigation with magnetic resonance imaging showed no obvious abnormality. Conservative treatment with lubricants resulted in progressive right corneal stromal loss, and no healing occurred in the left corneal ulcer. Bilateral large lateral tarsorrhaphies were performed. Despite this, the left corneal ulcer demonstrated no improvement and increasing stromal opacification was noted. Topical nerve growth factor (NGF) was then used to treat the left cornea and resulted in epithelial healing within 1 week. Treatment was continued for a further 10 days after epithelial healing. Despite conventional treatment on 3 separate occasions, further epithelial breakdown occurred. Topical NGF treatment resulted in a rapid improvement and healing of the epithelial defect.'At present, the patient is receiving a 6-month continuous treatment plan of NGF.
RESULTS: Persistent epithelial defects (PED) secondary to neurotrophic ulceration have responded to topical NGF on 3 separate occasions during a 2-year period. The corneal epithelium now remains intact, and the cornea has no vascularization; however, mild anterior stromal opacification has gradually increased despite prolonged NGF treatment.
CONCLUSION: NGF seems to represent a safe and efficacious treatment option to restore the integrity of corneal epithelium in which there is congenital corneal anesthesia because of trigeminal insufficiency. However, this treatment alone is insufficient to prevent progressive anterior stromal opacification.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16633039     DOI: 10.1097/01.ico.0000176609.42838.df

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  16 in total

1.  Recombinant expression of human nerve growth factor beta in rabbit bone marrow mesenchymal stem cells.

Authors:  Bo-Sheng Fan; Ji-Yu Lou
Journal:  Mol Biol Rep       Date:  2010-03-17       Impact factor: 2.316

2.  The TFOS International Workshop on Contact Lens Discomfort: report of the subcommittee on neurobiology.

Authors:  Fiona Stapleton; Carl Marfurt; Blanka Golebiowski; Mark Rosenblatt; David Bereiter; Carolyn Begley; Darlene Dartt; Juana Gallar; Carlos Belmonte; Pedram Hamrah; Mark Willcox
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-18       Impact factor: 4.799

Review 3.  In Vivo Confocal Microscopy of Corneal Nerves in Health and Disease.

Authors:  Andrea Cruzat; Yureeda Qazi; Pedram Hamrah
Journal:  Ocul Surf       Date:  2016-10-19       Impact factor: 5.033

4.  Nerve growth factor and its receptor TrkA serve as potential markers for human corneal epithelial progenitor cells.

Authors:  Hong Qi; De-Quan Li; H David Shine; Zhuo Chen; Kyung-Chul Yoon; Dan B Jones; Stephen C Pflugfelder
Journal:  Exp Eye Res       Date:  2007-09-15       Impact factor: 3.467

Review 5.  Corneal nerves in health and disease.

Authors:  Brittany Simmons Shaheen; May Bakir; Sandeep Jain
Journal:  Surv Ophthalmol       Date:  2014-01-23       Impact factor: 6.048

6.  Nerve growth factor promotes corneal epithelial migration by enhancing expression of matrix metalloprotease-9.

Authors:  Tomas Blanco-Mezquita; Carmen Martinez-Garcia; Rui Proença; James D Zieske; Stefano Bonini; Alessandro Lambiase; Jesus Merayo-Lloves
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-06-04       Impact factor: 4.799

7.  Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye.

Authors:  Karen Meerovitch; Gail Torkildsen; John Lonsdale; Heidi Goldfarb; Teresa Lama; Garth Cumberlidge; George W Ousler
Journal:  Clin Ophthalmol       Date:  2013-06-26

Review 8.  Neuropathic pain and dry eye.

Authors:  Anat Galor; Hamid-Reza Moein; Charity Lee; Adriana Rodriguez; Elizabeth R Felix; Konstantinos D Sarantopoulos; Roy C Levitt
Journal:  Ocul Surf       Date:  2017-10-12       Impact factor: 6.268

9.  Nerve growth factor regulates neurolymphatic remodeling during corneal inflammation and resolution.

Authors:  Darci M Fink; Alicia L Connor; Philip M Kelley; Maria M Steele; Michael A Hollingsworth; Richard M Tempero
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

10.  Congenital hypoplastic trigeminal nerve revealed by manifestation of corneal disorders likely caused by neural factor deficiency.

Authors:  Naoyuki Morishige; Yukiko Morita; Naoyuki Yamada; Teruo Nishida; Koh-Hei Sonoda
Journal:  Case Rep Ophthalmol       Date:  2014-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.